CAJ | 학술논문

目的观察阿伦膦酸钠对绝经后妇女原发性骨质疏松症的有效性和安全性。方法绝经后骨质疏松患者130例，将患者完全随机分成观察组及对照组，各65例。观察组每周口服阿伦膦酸钠70mg和元素钙(碳酸钙)及骨化醇；对照组口服元素钙(碳酸钙)及骨化醇。疗程均为12个月；通过骨密度仪观察治疗前及治疗后的骨密度的变化。结果治疗12个月后，观察组L2～4和股骨颈平均骨密度明显高于治疗前和对照组治疗后[L2～4：（844±116）mg/cm3比（788±76）mg/cm3、（785±64）mg/cm3；股骨颈：（681±71）mg/cm3比（644±72）mg/cm3、（662±90）mg/cm3]，差异均有统计学意义（P<0.05或P<0.01)。治疗过程中未发现与药物有关的不良反应。结论阿伦膦酸钠治疗绝经后骨质疏松症有效且安全。
목적관찰아륜련산납대절경후부녀원발성골질소송증적유효성화안전성。방법절경후골질소송환자130례，장환자완전수궤분성관찰조급대조조，각65례。관찰조매주구복아륜련산납70mg화원소개(탄산개)급골화순；대조조구복원소개(탄산개)급골화순。료정균위12개월；통과골밀도의관찰치료전급치료후적골밀도적변화。결과치료12개월후，관찰조L2～4화고골경평균골밀도명현고우치료전화대조조치료후[L2～4：（844±116）mg/cm3비（788±76）mg/cm3、（785±64）mg/cm3；고골경：（681±71）mg/cm3비（644±72）mg/cm3、（662±90）mg/cm3]，차이균유통계학의의（P<0.05혹P<0.01)。치료과정중미발현여약물유관적불량반응。결론아륜련산납치료절경후골질소송증유효차안전。
Objective To determine the efficiency and safety of alendronate on primary osteoporosis in postmenopausal women. Methods One hundred and thirty cases of postmenopausal women with osteoporosis were randomly divided into 2 group(control group and treatment group). All subjects in treatment group received alendronate 70 mg weekly.All patients received supplemental calcium and alfacalcidol orally daily for 12 months . Results Bone mineral density of L2~4 and femur neck in treatment group after treatment for 12 months were more than those before treatment and those in control group after treatment for 12 months[L2~4:(844±116)mg/cm3、(788±76)mg/cm3、(785±64)mg/cm3;neck of femur:(681±71)mg/cm3、(644±72)mg/cm3、(662±90)mg/cm3] and there were significant differences(P<0.05 or P<0.01). During treatment, drug related adverse reactions were occurred. Conclusion Alendonate is well effective and safe at doses of 70 mg weekly in the treatment of primary osteoporosis in postmenopausal women.